Expert Interview
A look at the Phase 1/2 data from Incyte’s first-in-class targeted monoclonal antibody, INCA033989, in patients with mutant calreticulin -expressing myeloproliferative neoplasms.
Ticker(s): INCYInstitution: Stanford
- Associate professor of medicine at Stanford.
- Treats 25-30 patients with NPM1 mutated AML and 10 mutated acute leukemias.
- Research interest focuses on the development of novel therapeutic regimens for patients with acute leukemia, with special interest in the development of novel therapeutic strategies for patients with acute myeloid leukemia.
- Leader in several institutional investigator initiated clinical trials, active investigator in collaborative multi-institutional clinical studies and an active member of the SWOG acute leukemia panel.
What are your impressions of the safety and efficacy signals observed in the dose escalation phase of INCA033989, particularly in the context of high-risk essential thrombocythemia patients resistant or intolerant to prior cytoreductive therapy?
Added By: sara_adminHow promising do you find the strategy of targeting mutant calreticulin directly with a monoclonal antibody, and what advantages might this offer compared to existing JAK inhibitors in MPNs?
Added By: sara_adminWhat additional data or endpoints would you need to see in order to consider INCA033989 a viable addition to the MPN treatment landscape?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
